How Could We Influence Systemic Inflammation in Allergic Rhinitis? The Role of H1 Antihistamines

Abstract EN

The aim of the study was the analysis of adhesion molecules’ profile (ICAM-1, VCAM-1, and E-selectin) in patients with allergic rhinitis and the influence of H1 antihistamines on those markers.

Seventy-nine patients with persistent allergic rhinitis (PAR) and 30 healthy volunteers were included in the study.

The patients with PAR were treated with desloratadine 5 mg/day or levocetirizine 5 mg/day for 4 weeks.

The clinical (rhinitis symptoms and total symptoms score (TSS), type of sensitization) and biological evaluation (total IgE, eosinophils, ICAM-1, VCAM-1, and E-selectin) as well as fractionate nitric oxide in exhaled air (FeNO) measurement was performed before and after treatment.

The plasmatic levels of ICAM-1, VCAM-1, total IgE, and eosinophils and FeNO were significantly increased in patients with PAR compared to healthy volunteers.

H1 antihistamines significantly improved TSS, with no differences between the investigated drugs.

There was a significant decrease of eosinophils, total IgE, and FeNO after treatment.

H1 antihistamines significantly decreased the plasmatic levels of ICAM-1 and E-selectin but not VCAM-1 compared to basal values.

There is no difference between levocetirizine and desloratadine in the reduction of CAMs.

A systemic inflammation characterized by increased levels of CAMs is present in patients with PAR.

H1 antihistamines improve symptoms and reduce CAMs and FeNO levels after 1 month of treatment.

H1 antihistamines might reduce the systemic inflammation which could be responsible to asthma occurrence in patients with PAR.